WBWilliam Barnett

William Barnett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William Barnett has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detection of Ventilator-Associated Events Among Adults: Comparing a Naïve Bayes Classifier and Logistic Regression

    by William Barnett, James Bassett, Chad Jaenke, Zachary Holtzapple, Kiran Boyinepally, Warren Back, Aadil Maqsood, Fadi Safi, Ragheb Assaly

    A Naïve Bayes classifier was used to identify mechanically ventilated patients at risk for ventilator-associated events (VAEs). VAEs, which can lead to ventilator-associated pneumonia (VAP), are considered preventable and have therefore been extensively studied. Data were gathered from May 2013 to August 2016 from hospital surveillance records and matched 1:1 with non-VAE cases using age, sex, unit while intubated, use of vasopressors, and total ventilator days. The dataset was split 7:3 to create samples for training and testing. From the training set, the classifier calculated the conditional probabilities for each factor in the model. After the proposed model was trained, it was validated against the testing data sample. The model demonstrated an overall accuracy of 83.0% (95% CI; 74.8% – 89.5%) and was able to correctly classify 80.4% of VAEs (sensitivity) and 85.7% of non-VAEs (specificity). The PPV and NPV were 81.4% and 84.9%, respectively. The AUC was 0.831 (95% CI; 0.751 – 0.911) and the MCC was 0.662. This study indicates that a Naïve Bayes classifier can be used to classify mechanically ventilated patients at risk for VAEs with moderate accuracy. The model could be used to screen for VAEs at the time of intubation and to strengthen manual surveillance. Further research is needed to validate the model in terms of prognostic and diagnostic use for hospitals and clinical settings with different patient characteristics.

  • Open Access

    The Evaluation of a Pharmacist-Led Multidisciplinary Quality Committee in a General Internal Medicine Outpatient Clinic

    by Marilee Clemons, Sarah Aldrich Renner, William Barnett

    Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.

  • Open Access

    Risk Factors Associated With Six-Month Mortality in Hospitalized COVID-19 Patients: A Single-Institution Study

    by Navkirat Kahlon, Jasskiran Kaur, Sishir Doddi, Cameron Burmeister, Taha Sheikh, Ziad Abuhelwa, Aya Abugharbyeh, Ragheb Assaly, William Barnett, Danae Hamouda

    Coronavirus disease 2019 (COVID-19) infection can vary from asymptomatic infection to multi-organ dysfunction. The most serious complication of infection with COVID-19 is death. Various comorbid conditions and inflammatory markers have been associated with an increased risk of mortality, specifically within the immediate post-infection period; however, less is known about long-term mortality outcomes. Our objective is to determine risk factors associated with six-month mortality in hospitalized COVID-19 patients. This is a single-institution, retrospective study. We included patients hospitalized with COVID-19 from the University of Toledo Medical Center in Toledo, Ohio, who were admitted from March 20, 2020, to June 30, 2021. This study was approved by a biomedical institutional review board at the University of Toledo. Patients with available pre-stored blood samples for laboratory testing were included, and hospital charts were assessed up to six months from the date of a positive COVID-19 test result. Two groups were created based on the mortality outcome at six months from COVID-19 positive test results: survivors and non-survivors. The clinical variables or outcomes and laboratory values were compared between the two groups using non-parametric methods due to the small sample size and non-normality of the data. Either the Mann-Whitney U-test for continuous variables or Fisher’s exact test for categorical variables was used for statistical analysis. Lactate dehydrogenase (LDH) and D-dimer levels on admission were found to be significantly higher in non-survivors than in survivors. The median high D-dimer level in non-survivors was 5.96 micrograms/milliliter (μg/mL) (interquartile range (IQR): 3.95-11.29 μg/mL) vs 1.82 μg/mL (IQR 1.13-5.55 μg/mL) in survivors (p = 0.019). Median LDH levels were also higher in non-survivors vs survivors, i.e., 621.00 international units per liter (IU/L) (IQR 440.00-849.00 IU/L) vs 328.00 IU/L (IQR 274.00-529.00 IU/L), respectively (p = 0.032). The demographic profile, comorbidity profile, and laboratory data (typically associated with short-term mortality, inflammation, and organ dysfunction) were similar between survivors and non-survivors, except for LDH and D-dimer. Higher LDH and D-dimer levels on admission were found to be associated with an increased six-month mortality rate in hospitalized COVID-19 patients. These hematologic data can serve as risk stratification tools to prevent long-term mortality outcomes and provide proactive clinical care in hospitalized COVID-19 patients.


  • Open Access

    Prevalence and Clinical Significance of Antiphospholipid Antibodies in Hospitalized Patients With COVID-19 Infection

    by Navkirat Kahlon, Pejma Shazadeh Safavi, Ziad Abuhelwa, Taha Sheikh, Cameron Burmeister, Sishir Doddi, Ragheb Assaly, William Barnett

    Background: Coronavirus disease 2019 (COVID-19) infection is associated with an increased risk of arterial thromboembolic events (ATE) and venous thromboembolic events (VTE). Hypercoagulability associated with COVID-19 infection is multifactorial, and underlying pathogenic mechanisms potentially responsible for thrombosis include inflammation resulting in endothelial damage, platelet activation and the presence of antiphospholipid antibodies (APAs). Antiphospholipid antibody syndrome is one of the very few causes which is associated with venous and arterial thromboembolic events. COVID-19 patients have a high prevalence of APAs as well as both ATE and VTE, but their clinical significance in COVID-19 patients is not fully understood yet. Objectives: In this study, we intend to find the prevalence of APAs in hospitalized COVID-19 patients at the time of diagnosis and determine whether their presence has any clinical significance. Methods: This is a retrospective single-institution study involving patients hospitalized for the management of COVID-19 infection at The University of Toledo Medical Center. After obtaining approval from the biomedical institutional review board at The University of Toledo, antiphospholipid antibody (APA) testing was done on pre-stored blood samples of these patients and hospital charts were reviewed till six months from the positive COVID-19 test result. Two groups were created based on the patients' APA testing results (APA positive and APA negative) and used for statistical comparison. Any patients with positive lupus anticoagulant (LA) or abnormal titers APA antibodies were labeled as positive. Demographic data, prognostic outcomes and laboratory values were compared either using Mann-Whitney U-test for continuous variables or Fisher’s exact test for categorical variables. Results: The prevalence of APAs in hospitalized COVID-19 patients at the time of diagnosis was 39.3% in this study. There was no difference in demographic variables between the APA-positive and APA-negative groups. The prevalence of APAs was higher in smokers, where 91% of the APA-positive patients were smokers. There was no statistically significant difference in prognostic outcomes including six-month mortality between APA-positive and APA-negative patients. The comorbidity profile was the same in the two groups. APA-positive patients were found to have lower nadir of absolute lymphocyte count and higher nadir levels of C-reactive protein during hospitalization. Conclusions: The prevalence of APA positivity in hospitalized COVID-19 patients is higher in our study than in historical studies involving non-COVID-19 hospitalized patients, particularly in smokers. However, there is no correlation between APA positivity and prognostic outcomes including six-month mortality. At this point, it is unclear whether APAs are just bystanders or have a pathogenic role. Routine testing of APA in COVID-19 patients is not indicated. Further prospective studies to elucidate the persistence and clinical implications of APAs are needed.


  • Open Access

    440. Detection of COVID-19 Patients Requiring Escalation to ICU Status Using a Naïve Bayes Classifier

    by William R Barnett, Chad Jaenke, Zachary Holtzapple, James Williams, Nithin Kesireddy, Waleed Khokher, Ragheb Assaly

    A naïve Bayes classifier is a popular tool used in assigning variables an equal and independent contribution to a binary decision. With respect to COVID-19 severity, the naïve Bayes classifier can consider different variables, such as age, gender, race/ethnicity, comorbidities, and initial laboratory values to determine the probability a patient may need to be admitted or transferred to an intensive care unit (ICU). The aim of this study was to develop a screening tool to detect COVID-19 patients that may require escalation to ICU status. Patients hospitalized with COVID-19 were gathered from the end of March 2020 to the end of May 2020 from four hospitals in our metropolitan area. We began searching for potential variables to include in the classification model using chi-square analysis or calculating the optimal cutpoint to separate ICU and non-ICU status. After identifying significant variables, we began using standard procedures to construct a classifier. The dataset was split 7:3 to create samples for training and testing. To appraise the model’s performance, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the curve (AUC), and the Matthew’s correlation coefficient (MCC) were calculated. Table 1. Univariate analysis of variables in the COVID-19 dataset dichotomized by ICU status A total of 574 COVID-19 patients were included in the study. There were 402 patients in the training sample and 172 patients in the testing sample. The naïve Bayes classifier demonstrated an overall accuracy result of 75.6% (95% CI; 68.5% – 81.8%) using the 14 variables listed in Table 1. The model was able to correctly classify 84.9% of ICU status patients (sensitivity), but only 54.7% of non-ICU status patients (specificity). The PPV and the NPV were 80.1% and 61.7%, respectively. The AUC was 0.717 (95% CI; 0.629 – 0.805) and the MCC was 0.410. Our naïve Bayes classifier operates by recognizing certain aspects of severe COVID-19 cases and looking for the probability of the variables in said patients. We present a classification model that potentially could be used alongside other tools to screen patients with COVID-19 early in their hospital course to identify those needing escalation to ICU level care. All Authors: No reported disclosures

  • Open Access

    Does a Starting Positive End-Expiratory Pressure of 8 cmH2O Decrease the Probability of a Ventilator-Associated Event?

    by William R. Barnett, Aadil Maqsood, Nithin Kesireddy, Waleed Khokher, Zachary Holtzapple, Fadi A. Safi, Ragheb Assaly

    Introduction: Ventilator-associated events (VAEs) are objective measures as defined by the Centers for Disease Control and Prevention (CDC). To reduce VAEs, some hospitals have started patients on higher baseline positive end-expiratory pressure (PEEP) to avoid triggering VAE criteria due to respiratory fluctuations.Methods: At our institution, VAEs were gathered from January 2014 through December 2019. Using the CDC-defined classifications, VAEs were split into two groups to separate patients with hypoxemia only (VAC) and those with hypoxemia and evidence of inflammation or infection (IVAC-plus). We used the geometric distribution to calculate the daily event probability before and after the protocol implementation. A probability threshold was used to determine if the days between events was exceeded during the post-protocol period.Results: A total of 306 VAEs were collected over the study period. Of those, 155 were VACs and 107 were IVAC-plus events during the pre-protocol period. After implementing the protocol, 24 VACs and 20 IVAC-plus events were reported. There was a non-significant decrease in daily event probabilities in both the VAC and IVAC-plus groups (0.083 vs. 0.068 and 0.057 vs. 0.039, respectively).Conclusion: We concluded a starting PEEP of 8 cmH2O is unlikely to be an effective intervention at reducing the probability of a VAE. Until specific guidelines by the CDC are established, hospitals should consider alternative methods to reduce VAEs.

  • Initial MEWS score to predict ICU admission or transfer of hospitalized patients with COVID-19: A retrospective study

    by William R. Barnett, Muthukumar Radhakrishnan, John Macko, Bryan T. Hinch, Nezam Altorok, Ragheb Assaly


  • Larger endotracheal tube size in women increase the risk for ventilator-associated events

    by William R. Barnett, Prabath Herath Mudiyanselage, Hossein Haghbin, Momen Banifadel, Josephine Adunse, Fadi Safi, Ragheb Assaly